Joyonna Gamble-George

Joyonna Gamble-George

Auto-generated profile, based on publicly available information

Joyonna Gamble-George

Department of Computer Science, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2012 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
OGO Gunduz-Cinar
O Gunduz-Cinar
KMK P MacPherson
K P MacPherson
RCResat Cinar
Resat Cinar
JGJ Gamble-George
J Gamble-George
KSK Sugden
K Sugden
AHA Holmes
A Holmes

8 July 2014 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
RBR J Bluett
R J Bluett
JGJ C Gamble-George
J C Gamble-George
DHD J Hermanson
D J Hermanson
NHN D Hartley
N D Hartley
LML J Marnett
L J Marnett
SPS Patel
S Patel
Stress is a major risk factor for the development of mood and anxiety disorders; elucidation of novel approaches to mitigate the deleterious effects of stress could have broad clinical applications. Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling may be an effective therapeutic strategy to mitigate the adverse behavioral and physiological consequences of stress. Here we show that acute foot-shock stress induces a transient anxiety state measured 24 h later using the light–dark box assay and novelty-induced hypophagia test. Acute pharmacological inhibition of the anandamide-degrading enzyme, fatty acid amide hydrolase (FAAH), reverses the stress-induced anxiety state in a cannabinoid receptor-dependent manner. FAAH inhibition does not significantly affect anxiety-like behaviors in non-stressed mice. Moreover, whole brain anandamide levels are reduced 24 h after acute foot-shock stress and are negatively correlated with anxiety-like behavioral measures in the light–dark box test. These data indicate that central anandamide levels predict acute stress-induced anxiety, and that reversal of stress-induced anandamide deficiency is a key mechanism subserving the therapeutic effects of FAAH inhibition. These studies provide further support that eCB-augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders.

4 August 2013 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
DHDaniel J Hermanson
Daniel J Hermanson
NHNolan D Hartley
Nolan D Hartley
JGJoyonna Gamble-George
Joyonna Gamble-George
NBNaoko Brown
Naoko Brown
BSBrian C Shonesy
Brian C Shonesy
SPSachin Patel
Sachin Patel
Enhancing endocannabinoid signaling is a potential therapeutic approach to treating anxiety disorders. Here the authors show that a compound leading to 'substrate-selective' inhibition of cyclooxygenase-2 (cox-2) increases endocannabinoid levels without affecting non-endocannabinoid lipids or prostaglandin synthesis. This compound decreased anxiety-like behaviors in mice via increased endocannabinoid signaling. Augmentation of endogenous cannabinoid (eCB) signaling represents an emerging approach to the treatment of affective disorders. Cyclooxygenase-2 (COX-2) oxygenates arachidonic acid to form prostaglandins, but also inactivates eCBs in vitro. However, the viability of COX-2 as a therapeutic target for in vivo eCB augmentation has not been explored. Using medicinal chemistry and in vivo analytical and behavioral pharmacological approaches, we found that COX-2 is important for the regulation of eCB levels in vivo. We used a pharmacological strategy involving substrate-selective inhibition of COX-2 to augment eCB signaling without affecting related non-eCB lipids or prostaglandin synthesis. Behaviorally, substrate-selective inhibition of COX-2 reduced anxiety-like behaviors in mice via increased eCB signaling. Our data suggest a key role for COX-2 in the regulation of eCB signaling and indicate that substrate-selective pharmacology represents a viable approach for eCB augmentation with broad therapeutic potential.

1 July 2014 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
DHDaniel J. Hermanson
Daniel J. Hermanson
JGJoyonna C. Gamble-George
Joyonna C. Gamble-George
LMLawrence J. Marnett
Lawrence J. Marnett
SPSachin Patel
Sachin Patel

27 December 2012 in Synapse
Verified
Journal Article
Closed access
PDF file
ANAshley North
Ashley North
JSJarod Swant
Jarod Swant
MSMichael F. Salvatore
Michael F. Salvatore
JGJoyonna Gamble‐George
Joyonna Gamble‐George
PPPetra Prins
Petra Prins
Habibeh KhoshboueiHabibeh Khoshbouei
Habibeh Khoshbouei

1 September 2017 in Neurobiology of Disease
Verified
Journal Article
Closed access
PGPeter J Gaskill
Peter J Gaskill
DMDouglas R. Miller
Douglas R. Miller
JGJoyonna Gamble-George
Joyonna Gamble-George
HYHideaki Yano
Hideaki Yano
Habibeh KhoshboueiHabibeh Khoshbouei
Habibeh Khoshbouei